财经快讯|通化东宝:公司利拉鲁肽注射液获得药品注册证书
通化东宝12月4日公告,公司于近日收到国家药品监督管理局核准签发的利拉鲁肽注射液《药品注册证书》。利拉鲁肽是一种人胰高血糖素样肽-1(GLP-1)类似物,可激活人GLP-1受体,促进胰腺分泌胰岛素。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!